Maxipime, an antimicrobial medicament, is classified as a fourth generation cephalosporin antibiotic and is used to treat moderate to severe pneumonia and other bacterial infections. Maxipime is rarely prescribed due to a Food & Drug Administration article regarding its safety. The article, Efficacy and Safety of Maxipime: A Systematic Review and Meta-analysis, was published in May 2007 in The Lancet Infectious Diseases. The article is a review of Maxipime's effectiveness and an increased mortality rate connected to its use.
Maxipime was developed in the early 1990s and marketed in 1994 under numerous trade names. It has been effective in treating both Gram-positive and Gram-negative organisms. Maxipime is used to treat complicated episodes of urinary tract infections, skin infections, and intra-abdominal infections in addition to pneumonia and other respiratory infections. It is also used as an Empiric Therapy for Febrile Neutropenic Patients. Maxipime's effectiveness over other antibacterial medicaments lies in its action against susceptible bacteria.
Maxipime is a liquid suspension given intravenously. It is injected into your large muscle in the hip, in the buttock or added to an intravenous fluid every 12 to 24 hours. Physician supervision is required during Maxipime use because the physician is the only one who can determine whether it is appropriate for your current illness or not. A patient taking Maxipime is closely watched to ensure that the effectiveness of the medicament is greater than its side effects. Physical examinations and laboratory testing are used to monitor the patient's progress.
The dosage per day and duration depend on the severity of the patient's condition as well as their medical history. Dosage adjustments are necessary for some patients. You must talk with your physician regarding your medical history. Patients with allergies, currently taking other medicines, have had bouts with kidney, liver, and gastrointestinal diseases, are pregnant, are planning to become pregnant or have diabetes are or particular concern. It is important for the patient's safety to follow the prescription exactly. Do not alter it without the consent of your physician. Ceasing to take Maxipime due to an improvement of your symptoms might give the bacteria enough space to thrive and cause more damage.
Some known side effects include diarrhea, stomach pain, and emesis. If symptoms persist or worsen, call your physician immediately. Skin rash, breathing difficulty, unusual bleeding or easy bruising, hives and sore throat are not common side effects for patients under Maxipime therapy. If any of these symptoms occur at any point of your treatment, call your physician.
Since the FDA has doubts regarding Maxipime's safety, it would be best to ask for an alternative medicament you could use for your condition. If your physician insists on Maxipime, make sure you are monitored closely to be safe.
Maxipime has the following structural formula:
• Molecular formula of maxipime is C19H24N6O5S2
• Chemical IUPAC Name is (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]- 3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
• Molecular weight is 480.5611 g/mol
• Maxipime available : 100mg tablets
©2007-2017 Medicalook.com All rights reserved